Advisor OS LLC Has $943,000 Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Advisor OS LLC reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 25,405 shares of the company’s stock after selling 628 shares during the period. Advisor OS LLC’s holdings in Amphastar Pharmaceuticals were worth $943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Pacer Advisors Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after acquiring an additional 1,347,775 shares during the period. Boston Trust Walden Corp lifted its holdings in Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after purchasing an additional 439,281 shares during the last quarter. Hotchkis & Wiley Capital Management LLC bought a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at $10,804,000. Portolan Capital Management LLC grew its holdings in Amphastar Pharmaceuticals by 201.1% in the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock valued at $15,906,000 after buying an additional 218,901 shares in the last quarter. Finally, Weiss Asset Management LP bought a new position in Amphastar Pharmaceuticals during the 3rd quarter worth $4,967,000. 65.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the transaction, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the transaction, the director now directly owns 30,471 shares of the company’s stock, valued at $1,333,715.67. This trade represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $31.99 on Wednesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a 52-week low of $30.34 and a 52-week high of $56.38. The firm has a market cap of $1.54 billion, a P/E ratio of 10.66, a price-to-earnings-growth ratio of 2.19 and a beta of 0.81. The business’s fifty day moving average is $35.27 and its 200-day moving average is $42.83.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th. Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average price target of $50.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.